Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics
REDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately. Craig Christianson has been appointed Chief Executive Officer following an extensive search process. Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor. Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR.
- Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor.
- Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR.
- "Founding and growing Synthego the past 12 years has been the privilege of a lifetime," said Dabrowski.
- As the world enters the era of CRISPR based therapeutics, Synthego is now focused to be the premier supplier to hundreds of programs entering the clinic."